μ-Opioid receptor activation prevents acute hepatic inflammation and cell death

Chakass, Dania; Philippe, David; Erdual, Edmone; Dharancy, Sébastien; Malapel, Mathilde; Dubuquoy, Caroline; Thuru, Xavier; Gay, Jerome; Gaveriaux-Ruff, Claire; Dubus, Pierre; Mathurin, Philippe; Kieffer, Brigitte I.; Desreumaux, Pierre; Nestlé, Mathias Chamaillard
July 2007
Gut;Jul2007, Vol. 56 Issue 7, p974
Academic Journal
Background and aims: The detrimental impact of opioid agonist on the clinical management of inflammatory diseases remains elusive. Given the anti-inflammatory properties of the μ-opioid receptor (MOR) agonists at the intestinal barrier, we hypothesised that MOR activation might also dampen acute hepatic inflammation and cell death-major determinants in the pathogenesis of liver diseases. Patients and methods: The expression of MOR in liver biopsy specimens and peripheral blood mononuclear cells of untreated patients with chronic hepatitis C virus infection and controls, primary hepatocytes and cell lines was determined by quantitative PCR, immunoblotting and/or immunohistochemistry. The effects of peripheral MOR agonist (D-Ala2,NMe-Phe4,Gly5-ol (DAMGO)) and/or antagonist (naloxone methiodide) were explored in two models of acute hepatitis in mice. MOR-deficient mice were used to evaluate the essential regulatory role of MOR during carbon tetrachloride (CCI4)-induced hepatitis. The role of DAMGO in cell death was investigated using terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling (TUNEL) analysis and quantification of lactate dehydrogenase release. Results: The key role of MOR in the prevention of acute hepatic inflammation and cell death in vivo and in vitro is reported. Whereas MOR gene expression increased transiently in the model of acute liver injury and TNFα-treated HepG2 cells, an impaired expression of MOR mRNA in human chronic hepatitis C samples was found. Furthermore, preventive administration of the selective MOR agonist DAMGO enhanced hepatoprotective-signalling pathways in vivo that were blocked by using naloxone methiodide. Consistently, genetic and pharmacological inhibition of MOR enhanced the severity associated with experimental hepatotoxin-induced hepatitis. Finally, treatment with DAMGO was shown to prevent cell death in vitro in HepG2 cells in a MOR-dependent manner and to prevent concanavalin A- and CCl4-induced cell death in vivo, providing a possible explanation for the anti-inflammatory role of MOR activation in the liver. Conclusions: The results indicate that MOR agonists may prevent acute hepatitis and hold promising therapeutic use to maintain remission in both chronic inflammatory bowel and liver diseases.


Related Articles

  • Renal Impairment with Sublethal Tubular Cell Injury in a Chronic Liver Disease Mouse Model. Ishida, Tokiko; Kotani, Hirokazu; Miyao, Masashi; Kawai, Chihiro; Jemail, Leila; Abiru, Hitoshi; Tamaki, Keiji // PLoS ONE;1/11/2016, Vol. 11 Issue 1, p1 

    The pathogenesis of renal impairment in chronic liver diseases (CLDs) has been primarily studied in the advanced stages of hepatic injury. Meanwhile, the pathology of renal impairment in the early phase of CLDs is poorly understood, and animal models to elucidate its mechanisms are needed. Thus,...

  • Sustained survival of human hepatocytes in mice: A model for in vivo infection with human hepatitis B and hepatitis delta viruses. Ohashi, Kazuo; Marion, Patricia L.; Nakai, Hiroyuki; Meuse, Leonard; Cullen, John M.; Bordier, Bruno B.; Schwall, Ralph; Greenberg, Harry B.; Glenn, Jeffrey S.; Kay, Mark A. // Nature Medicine;Mar2000, Vol. 6 Issue 3, p327 

    Persistence of hepatocytes transplanted into the same or related species has been established. The long-term engraftment of human hepatocytes into rodents would be useful for the study of human viral hepatitis, where it might allow the species, technical and size limitations of the current...

  • Osteopontin neutralisation abrogates the liver progenitor cell response and fibrogenesis in mice. Coombes, J. D.; Swiderska-Syn, M.; Dollé, L.; Reid, D.; Eksteen, B.; Claridge, L.; Briones-Orta, M. A.; Shetty, S.; Oo, Y. H.; Riva, A.; Chokshi, S.; Papa, S.; Mi, Z.; Kuo, P. C.; Williams, R.; Canbay, A.; Adams, D. H.; Diehl, A. M.; van Grunsven, L. A.; Choi, S. S. // Gut;Jul2015, Vol. 64 Issue 7, p1120 

    Background Chronic liver injury triggers a progenitor cell repair response, and liver fibrosis occurs when repair becomes deregulated. Previously, we reported that reactivation of the hedgehog pathway promotes fibrogenic liver repair. Osteopontin (OPN) is a hedgehogtarget, and a cytokine that is...

  • Deficiency in four and one half LIM domain protein 2 (FHL2) aggravates liver fibrosis in mice. Huss, Sebastian; Stellmacher, Christian; Goltz, Diane; Khlistunova, Inna; Adam, Alexander C.; Trebicka, Jonel; Kirfel, Jutta; Büttner, Reinhard; Weiskirchen, Ralf // BMC Gastroenterology;2013, Vol. 13 Issue 1, p1 

    Background: Four and one half LIM domain protein 2 (FHL2) has been reported to be a key regulator in many cellular processes being associated with fibrogenesis such as cell migration and contraction. Moreover, hepatic FHL2 is involved in regulation pathways mediating proliferation and cell death...

  • Hepatocarcinogenesis in hepatitis viral infection: lessons from transgenic mouse studies. Koike, Kazuhiko // Journal of Gastroenterology;2002 Supplement 13, Vol. 37, p55 

    Over the past decade, genetically engineered mouse models have been used for studies of the mechanisms underlying human diseases. One advantage of these models is that the targeted protein executes its function in normal cells in their natural tissue microenvironments. Transgenic mouse models...

  • Aberrant transcription and post-transcriptional processing of hepatitis C virus non-structural genes in transgenic mice. Desai, Mayura; Tumurbataar, Batbayar; Zhang, Yueqing; Chan, Lee-Nien; Sun, Jiaren; Chan, Teh-sheng // Transgenic Research;Dec2011, Vol. 20 Issue 6, p1273 

    Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease worldwide. Since several aspects of the infection remain unresolved, there is a pressing need for a convenient animal model that can mimic the clinical disease and aid the evaluation of treatment strategies. Although...

  • Constitutive active/androstane receptor promotes hepatocarcinogenesis in a mouse model of non-alcoholic steatohepatitis. Takizawa, Daichi; Kakizaki, Satoru; Horiguchi, Norio; Yamazaki, Yuichi; Tojima, Hiroki; Mori, Masatomo // Carcinogenesis;Apr2011, Vol. 32 Issue 4, p576 

    The nuclear receptor constitutive active/androstane receptor (CAR) acts as a sensor of toxic byproducts derived from the endogenous metabolism and exogenous chemicals. We previously reported that CAR is responsible for exacerbating hepatic injury and fibrosis in a dietary model of non-alcoholic...

  • Alterations of Bone Marrow Sinusoidal Endothelium in Rat and Patients with Liver Cirrhosis. Song Zhao; Ying-Mei Fu; Xiu-Fen Li; Zhan-Feng Jin; Rui-Bo Zhao; Qi Huang; Feng-Min Zhang; Wei-Hui Zhang // Digestive Diseases & Sciences;Mar2010, Vol. 55 Issue 3, p654 

    Whether bone marrow changes occur and potentially contribute to the hematological abnormalities in liver cirrhosis remain unclear. In this study, we established a rat model of liver cirrhosis induced by carbon tetrachloride. Electron microscopy examination showed focal lesions in bone marrow...

  • Therapeutic Effects of Rapamycin on MPTP-Induced Parkinsonism in Mice. Liu, Kangyong; Shi, Nan; Sun, Yinyi; Zhang, Ting; Sun, Xiaojiang // Neurochemical Research;Jan2013, Vol. 38 Issue 1, p201 

    In neurodegenerative disorders such as Parkinson's disease (PD), autophagy is implicated in the process of dopaminergic neuron cell death. The α-synuclein protein is a major component of Lewy bodies and Lewy neurites, and mutations in α-synuclein have been implicated in the etiology of...


Read the Article


Sign out of this library

Other Topics